All News Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
17.15 ^USD	-0.58%		+16.59%	+151.47%

14/03	Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	MT
14/03	Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024	26/04	AQ
Y-mAbs to Present at 2024 ASCO Annual Meeting	26/04	AQ
Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	14/03	MT
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	14/03	CI
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer	14/03	AQ
Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer	14/03	CI
HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating	06/03	MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating	04/03	MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating	04/03	MT
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors	04/03	AQ
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors	04/03	CI
Y mAbs Therapeutics : mAbs Appoints Oncolog Executive Mar Tagliaferri, M.D. to its Board of Directors - Form 8-K	04/03	PU
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating	04/03	MT
Transcript : Y-mAbs Therapeutics, Inc., Q4 2023 Earnings Call, Mar 01, 2024	01/03
Y-mAbs Therapeutics Surges 18% in Premarket Activity Following Q4 Results; Reiterates Anticipated Cash Runway into 2027	01/03	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/03	CI
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Reports Q4 Revenue $23.4M, vs. Street Est of $21M	01/03	MT
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	01/03	AQ
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	01/03	CI
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

All News

Filters